JP2016505043A - 免疫プログラミングおよび癌の治療のための選択的グリコシダーゼレジメン - Google Patents

免疫プログラミングおよび癌の治療のための選択的グリコシダーゼレジメン Download PDF

Info

Publication number
JP2016505043A
JP2016505043A JP2015553844A JP2015553844A JP2016505043A JP 2016505043 A JP2016505043 A JP 2016505043A JP 2015553844 A JP2015553844 A JP 2015553844A JP 2015553844 A JP2015553844 A JP 2015553844A JP 2016505043 A JP2016505043 A JP 2016505043A
Authority
JP
Japan
Prior art keywords
cancer
glycosidase
patient
regimen
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015553844A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505043A5 (enExample
Inventor
クライン，エリス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2016505043A publication Critical patent/JP2016505043A/ja
Publication of JP2016505043A5 publication Critical patent/JP2016505043A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01049—Alpha-N-acetylgalactosaminidase (3.2.1.49)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01051—Alpha-L-fucosidase (3.2.1.51)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
JP2015553844A 2013-01-18 2014-01-17 免疫プログラミングおよび癌の治療のための選択的グリコシダーゼレジメン Pending JP2016505043A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361754056P 2013-01-18 2013-01-18
US61/754,056 2013-01-18
PCT/US2014/011995 WO2014113641A1 (en) 2013-01-18 2014-01-17 Selective glycosidase regimen for immune programming and treatment of cancer

Publications (2)

Publication Number Publication Date
JP2016505043A true JP2016505043A (ja) 2016-02-18
JP2016505043A5 JP2016505043A5 (enExample) 2017-02-23

Family

ID=51210082

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015553844A Pending JP2016505043A (ja) 2013-01-18 2014-01-17 免疫プログラミングおよび癌の治療のための選択的グリコシダーゼレジメン

Country Status (9)

Country Link
US (2) US20150352193A1 (enExample)
EP (2) EP3563864A1 (enExample)
JP (1) JP2016505043A (enExample)
KR (1) KR20150107738A (enExample)
CN (1) CN104936611A (enExample)
AU (2) AU2014207429B2 (enExample)
CA (1) CA2896899A1 (enExample)
MX (1) MX2015009260A (enExample)
WO (1) WO2014113641A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022538895A (ja) * 2019-07-03 2022-09-06 パレオン ファーマシューティカルズ インコーポレイテッド 組換えシアリダーゼおよびその使用方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2805795T3 (es) 2012-09-28 2021-02-15 Ellis Kline Régimen de glicosidasa para el tratamiento de enfermedades infecciosas
WO2016162867A1 (en) * 2015-04-08 2016-10-13 Efranat Ltd. Combination therapy of macrophage activating factor and pd-1 signaling inhibitors
CN105256036B (zh) * 2015-10-26 2019-02-12 中国人民解放军第二军医大学 一种检测血清中lncARSR的试剂盒及其在检测肾癌舒尼替尼耐药中的应用
US11554145B2 (en) 2019-01-31 2023-01-17 The Chinese University Of Hong Kong Therapeutic and prophylactic treatment for colorectal cancer
CN111500715B (zh) * 2019-01-31 2022-03-11 北京大学 用于预测结直肠癌术后复发与转移的检测组合物、检测装置、检测试剂盒及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11511962A (ja) * 1995-06-07 1999-10-19 信人 山本 クローン化したビタミンｄ結合タンパク質由来の大食細胞活性化因子
US20010036455A1 (en) * 2000-04-07 2001-11-01 Kline Ellis L. Methods and compositions for treating neoplasms
JP2010532389A (ja) * 2007-07-03 2010-10-07 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド ポリシアル酸誘導体、製造方法、ならびにがん抗原産生の増強およびターゲティングにおける使用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4071408A (en) 1976-11-01 1978-01-31 Research Corporation Neuraminidase
DE3302160A1 (de) 1983-01-22 1984-07-26 Ing. Erich Pfeiffer GmbH & Co KG, 7760 Radolfzell Betaetigbare dosiereinrichtung
DE3315334A1 (de) 1983-04-28 1984-10-31 Pfeiffer Erich Gmbh & Co Kg Zerstaeuber- oder dosierpumpe
DE3715301A1 (de) 1987-05-08 1988-11-24 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung fuer medien
DE3722469A1 (de) 1987-07-08 1989-01-19 Pfeiffer Erich Gmbh & Co Kg Handbetaetigbare austragvorrichtung fuer medien
US5326749A (en) 1989-11-20 1994-07-05 Nobuto Yamamoto Macrophage activating factor from vitamin D binding protein
IT1252228B (it) 1991-12-17 1995-06-05 T Associated Bio Technologies Procedimento per la produzione di neuraminidasi
US6562588B2 (en) 1993-05-17 2003-05-13 Genentech, Inc. Sialidase and recombinant cell lines
US5985859A (en) 1994-04-14 1999-11-16 The University Of Alabama Methods of inhibiting bacterial sialidase
DE19525734A1 (de) 1995-07-14 1997-01-16 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für fließfähige Medien, insbesondere für den Austrag in nur einem Hub
DE10146815B4 (de) 2001-09-18 2005-05-04 Ing. Erich Pfeiffer Gmbh Spender für Medien
CA2460651C (en) 2001-09-21 2011-06-07 Ing. Erich Pfeiffer Gmbh Dosing device with a pumping device
DE10164452A1 (de) 2001-12-21 2003-07-03 Pfeiffer Erich Gmbh & Co Kg Spender für Medien
EP2261368A1 (en) 2002-03-13 2010-12-15 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2005039382A2 (en) 2003-06-24 2005-05-06 Genomic Health Prediction of likelihood of cancer recurrence
EP1644858B1 (en) 2003-07-10 2017-12-06 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
US7892752B2 (en) * 2005-04-26 2011-02-22 Dwek Raymond A Glycosylation markers for cancer diagnosing and monitoring
EP2084527A4 (en) * 2006-11-02 2011-07-27 Seattle Genetics Inc METHOD FOR TREATING NEOPLASIA, AUTOIMMUNE AND INFLAMMATORY DISEASES
EP2113027B1 (en) 2007-02-20 2014-06-18 DSM IP Assets B.V. Novel sialidase
AU2009246009A1 (en) 2008-05-14 2009-11-19 University Health Network Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
US20110238322A1 (en) 2008-11-03 2011-09-29 Precision Therapeutics, Inc. Methods of simulating chemotherapy for a patient
US20100331210A1 (en) 2009-05-29 2010-12-30 Precision Therapeutics, Inc. Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
IN2012DN02200A (enExample) * 2009-08-22 2015-08-21 Charles Knezevich
EP2687218B1 (en) * 2011-09-14 2016-07-13 Saisei Mirai Clinic Pharmaceutical composition and manufacturing method therefor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11511962A (ja) * 1995-06-07 1999-10-19 信人 山本 クローン化したビタミンｄ結合タンパク質由来の大食細胞活性化因子
US20010036455A1 (en) * 2000-04-07 2001-11-01 Kline Ellis L. Methods and compositions for treating neoplasms
JP2010532389A (ja) * 2007-07-03 2010-10-07 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド ポリシアル酸誘導体、製造方法、ならびにがん抗原産生の増強およびターゲティングにおける使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANTICANCER RESEARCH, 2004, VOL.24, PP.139-144, JPN6019020635, ISSN: 0004049531 *
IUBMB ENZYME NOMENCLATURE, EC3.2.1.18, ACCEPTED NAME:EXO-Α-SIALIDASE, [RETRIEVED ON 2019.05.28], RE, JPN6019020633, ISSN: 0004049530 *
堀均ほか: "Ｇｃタンパク質（ビタミンＤ結合タンパク質）の糖鎖プロセシングをベースとしたドラマタイプがん治療薬の創", 放射線生物研究, vol. 39, no. 3, JPN6012054574, 2004, pages 328 - 341, ISSN: 0004049529 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022538895A (ja) * 2019-07-03 2022-09-06 パレオン ファーマシューティカルズ インコーポレイテッド 組換えシアリダーゼおよびその使用方法

Also Published As

Publication number Publication date
AU2014207429B2 (en) 2018-11-01
AU2019200688B2 (en) 2020-08-06
US20150352193A1 (en) 2015-12-10
KR20150107738A (ko) 2015-09-23
WO2014113641A1 (en) 2014-07-24
MX2015009260A (es) 2015-10-15
AU2014207429A1 (en) 2015-07-02
EP3563864A1 (en) 2019-11-06
EP2945644A4 (en) 2016-10-26
CN104936611A (zh) 2015-09-23
US20190201503A1 (en) 2019-07-04
CA2896899A1 (en) 2014-07-24
AU2019200688A1 (en) 2019-02-21
EP2945644A1 (en) 2015-11-25

Similar Documents

Publication Publication Date Title
AU2019200688B2 (en) Selective glycosidase regimen for immune programming and treatment of cancer
Zeh III et al. Addicted to death: invasive cancer and the immune response to unscheduled cell death
JP7175334B2 (ja) 免疫刺激剤による癌治療
EP2684569A1 (en) A composition for treatment of advanced prostate cancer
CN103797025B (zh) 用精氨酸脱亚氨酶治疗的方法
US20170340658A1 (en) Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
JP6382934B2 (ja) 癌治療のためのａｄｉ−ｐｅｇ２０抗体に対して低減された交差反応性を有するアルギニンデイミナーゼ
CN108295087A (zh) 弗林蛋白酶敲减和gm-csf增强的（fang）癌症疫苗
JP2020503252A (ja) Ｔ細胞応答を促進するための方法
JP2024059767A (ja) 癌治療のための方法及び医薬組成物
US9480725B2 (en) Fermented wheat germ proteins (FWGP) for the treatment of cancer
Shurin et al. Low-dose chemotherapeutic agents regulate small Rho GTPase activity in dendritic cells
WO2015157299A2 (en) Inhibition of lactate dehydrogenase 5 (ldh-5) binding, incorporation, internalization and/or endocytosis to immune cells
AU2001251336B2 (en) Methods and compositions for treating neoplasms
CA2832376A1 (en) Drug containing recombinant mistletoe lectins for treating malignant melanoma
TW201408321A (zh) 治療癌症之協同組合
TWI676683B (zh) 用於癌症治療之對ａｄｉ－ｐｅｇ２０抗體交叉反應性降低之精胺酸去亞胺酶
Zhu et al. Radiotherapy followed by metformin neoadjuvant therapy drives superior pancreatic cancer ferroptosis and augments anti-tumor immunity
Du et al. Adjusting the dose of traditional drugs combined
Alsanani et al. Stromal carcinoma associated fibroblasts promote drug resistance of human pancreatic cancer cells by modulation of ROS via CXCR4/CXCL12 signaling
WO2023247660A1 (en) Combination therapies
WO2023200865A2 (en) Cancer therapy
KR20230101286A (ko) K-ras 특이적 활성화 T 세포를 포함하는 폐 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
HK1193755A (en) A composition for treatment of advanced prostate cancer
NZ717492B2 (en) Administration of kynurenine depleting enzymes for tumor therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180817

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190605